A recent meta-analysis by Nan et al. reports that the addition of SGLT-2 inhibitors to insulin therapy in 7192 people with type 1 diabetes significantly but gradually reduced HbA1c, while reduction in body weight was the biggest in the 2–6-month period, after a plateau was reached [6]. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.